Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2026)

Vertex Pharmaceuticals has reported Long-Term Deferred Tax for 10 years, with the latest figure at $3.0 billion in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 11.03% year-over-year to $3.0 billion in Q2 2026; TTM through Jun 2026 was $3.0 billion, a 11.03% increase from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 24.31% from the prior year.
• Long-Term Deferred Tax was $3.0 billion for Q2 2026 at Vertex Pharmaceuticals, up from $2.9 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $3.0 billion in Q2 2026, with the low at $945.5 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $2.0 billion, with a median of $2.1 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax soared 48.71% in 2023, then climbed 11.03% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $1.2 billion in 2022, then soared by 45.33% to $1.8 billion in 2023, then climbed by 28.64% to $2.3 billion in 2024, then climbed by 24.31% to $2.9 billion in 2025, then increased by 3.9% to $3.0 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $3.0 billion (Q2 2026), $2.9 billion (Q1 2026), and $2.9 billion (Q4 2025), per Business Quant data.